
Inogen (INGN) Stock Forecast & Price Target
Inogen (INGN) Analyst Ratings
Bulls say
Inogen Inc. is strategically positioning itself for growth by enhancing synergies across various sales channels, revitalizing its direct-to-consumer approach, and strengthening business-to-business relationships, thereby expanding its market reach. The partnership with Yuwell for entry into the Chinese COPD market presents substantial long-term growth opportunities, as this market is approximately ten times larger than that of the United States. Additionally, the projected growth of portable oxygen concentrators (POCs) to account for 58% of the market within the next five years indicates a favorable trend that could significantly benefit Inogen's revenue prospects.
Bears say
Inogen Inc has faced significant challenges due to an oversized sales force that led to unprofitable operations, despite prior revenue growth. The company reported a 17% decline in B2B sales and a 28% decline in DTC sales in 2023, indicating a severe downturn in its sales channels. Additionally, the shift from higher-paying Medicare to lower-reimbursing private insurance and an increasing number of capped patients is further exacerbating the revenue decline, contributing to a negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Inogen and is not a guaranteed prediction by Public.com or investment advice.
Inogen (INGN) Analyst Forecast & Price Prediction
Start investing in Inogen (INGN)
Order type
Buy in
Order amount
Est. shares
0 shares